Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

there is a need for improving chemotherapy regimen for metastatic G3 NEC of GEP and Unknown origin and this goal may be achieved through more "personalized" chemotherapy regimen.the hypothesis is that mFOLFIRINOX regimen could be a good candidate for challenging the platinum-etoposide regimen in patients with metastatic G3 NEC of GEP or unknown origin. Furthermore, in order to get insights in the putative predictive biomarkers of efficacy of these two regimens, an effort toward a precise molecular characterization of these tumors is required in order to be able to define which subgroup of G3 N

Trial Details

NCT ID
NCT04325425
Phase
PHASE2
Sponsor
Centre Hospitalier Universitaire Dijon
Status
RECRUITING
Cancer Type
Pancreatic Neuroendocrine Pancreatic Cancer
Interventions
  • FOLFOXIRI Protocol
  • Cisplatin injection
Locations (sample)
  • Caen, France|49.18585,-0.35912
  • Dijon, France|47.31344,5.01391
  • Dijon, France|47.31344,5.01391
  • Limoges, France|45.83362,1.24759
  • St-Malo, France|48.64738,-2.00877

Key Eligibility Criteria

  • Grade 3 neuroendocrine carcinoma or high grade MiNEN with a grade 3 poorly differentiated neuroendocrine carcinoma component ≥30% of gastro-entero-…
  • Poorly differentiated
  • Small cell or large cell or non-small cell or non- typeable
  • Metastatic disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Neuroendocrine Pancreatic Cancer Trials on Trialify →